Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia

计划入组 89 人 · 首次发布于 2012 年 2 月 8 日

Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides

计划入组 56 人 · 首次发布于 2016 年 9 月 14 日

Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support

计划入组 27 人 · 首次发布于 2015 年 12 月 16 日

APOC3

ALN-AC3

III-30

Carlos Iii Health Institute

Spain

Triphase Research and Development III Corp.

Centro Nacional de Investigaciones Oncologicas CARLOS III

FDA Approves Plozasiran for Familial Chylomicronemia Syndrome, Marking Breakthrough in Rare Lipid Disorder Treatment

Amarin Reports Strong Q4 2025 Performance as VASCEPA/VAZKEPA Franchise Positioned to Benefit from Emerging Triglyceride Therapies

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia